Analyse Tyra Biosciences, Inc. (TYRA) — Kairos Score 58/100

À propos de Tyra Biosciences, Inc.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

Informations clés

🕴️ Activité des initiés (90 jours)

4 transactions — 1 achats et 0 ventes déclarés par les dirigeants de Tyra Biosciences, Inc..

🏦 Hedge Funds

15 fonds institutionnels déclarent une position sur TYRA dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur TYRA.

• Tyra Biosciences (TYRA) Stock Looks Expensive Against Its Book Value
• Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.